表紙
市場調查報告書

肝腎症候群市場:全球產業分析,規模,佔有率,成長,趨勢,預測(2019∼2027年)

Hepatorenal Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品編碼 920534
出版日期 內容資訊 英文 168 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肝腎症候群市場:全球產業分析,規模,佔有率,成長,趨勢,預測(2019∼2027年) Hepatorenal Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2019年11月15日內容資訊: 英文 168 Pages
簡介

本報告提供肝腎症候群市場相關調查,彙整市場趨勢與預測,市場規模,主要加入企業,各地區趨勢相關資訊。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 各類型概要
  • 產業趨勢
  • 市場趨勢
  • 促進因素與阻礙因素概要
  • 促進要素
  • 阻礙要素
  • 機會
  • 市場收益預測

第5章 主要趨勢

  • 開發平台分析
  • 各區各國法律規章方案
  • 主要的產業活動
  • 肝臟·腎臟疾病罹患率

第6章 市場分析:各類型

  • 簡介
  • 市場價值預測
    • 第一型肝腎症候群
    • 第二型肝腎症候群
  • 市場分析
  • 市場魅力度

第7章 市場分析:不同治療

  • 簡介
  • 市場價值預測
    • 治療藥
    • 外科治療
  • 市場分析
  • 市場魅力度

第8章 市場分析:各終端用戶

  • 簡介
  • 市場價值預測
    • 醫院·診所
    • 門診外科中心
    • 學術·研究機關
    • 其他
  • 市場分析
  • 市場魅力度

第9章 市場分析:各地區

  • 市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場分析
  • 市場魅力度

第10章 北美

第11章 歐洲

第12章 亞太地區

第13章 南美

第14章 中東·非洲

第15章 競爭環境

  • 企業簡介
目錄

Hepatorenal Syndrome Treatment Market - Scope of the Report

Analysts at Transparency Market Research, in their recently collated research report, have presented detailed analysis and objective insights on the potential growth of the hepatorenal syndrome treatment market. The report extensively brings out the dynamics of the hepatorenal syndrome treatment market that are currently affecting its landscape. This in-depth research report also has an extensive SWOT analysis of the leading industry heavyweights in the hepatorenal syndrome treatment market, in an attempt to gain information on industry strongholds as well as shed light on the areas of improvement. Special emphasis has been laid on the drivers, restraints, opportunities, and threats in the hepatorenal syndrome treatment market space. This gives stakeholders a holistic view of the hepatorenal syndrome treatment market, especially during the forecast period.

The study on the hepatorenal syndrome treatment market has also been conducted via thorough appraisal of Porter's Five Forces analysis. An extensive global research done on the market also strives to highlight the key trends in the HRS treatment market that are likely to propel its growth during the forecast period. Statistical assessments of hepatorenal syndrome treatment market growth have been carried out in terms of value (US$ Mn).

This is an attempt to let stakeholders understand what the growth strategies and underlying opportunities are that could enable them in making expert decisions in the expanding repertoire of the hepatorenal syndrome treatment market. Competitive analysis of key players in the hepatorenal syndrome treatment market by our researchers perhaps remains the most vital ingredient in giving insights about mergers, acquisitions, research & development, and technological innovations. These allow competitors to accelerate their growth in the right direction in the hepatorenal syndrome treatment market.

Hepatorenal Syndrome Treatment Market - Key Questions That Have Been Answered

Through statistical analysis, detailed figures have been arrived at, which describe the growth of the hepatorenal syndrome treatment market. Authors of this report, through a comprehensive study and intelligent analytics, have arrived at some key questions that give readers a holistic and refreshing perspective of the HRS treatment market landscape. Influential trends help answer critical questions related to the hepatorenal syndrome treatment market, some of which are listed below:

  • What are the key factors that are influencing the hepatorenal syndrome treatment market in each region?
  • What are the major developments that will take place in the hepatorenal syndrome treatment market during the forecasted period of 2019-2027?
  • What are the revenue figures of the global hepatorenal syndrome treatment market by type, treatment, end user, and region?
  • What are the prevalent trends and how do they affect the future scope of the hepatorenal syndrome treatment market?
  • How is the rising prevalence of hepatorenal syndrome going to influence the need for surgical and therapeutic treatment options in the hepatorenal syndrome treatment market landscape?
  • Hepatorenal Syndrome Treatment Market Report: Research Methodology
  • Qualitative and quantitative information on the hepatorenal syndrome treatment market is then culled by exhaustive research. Information on the hepatorenal syndrome treatment market has been sourced from Transparency Market Research's internal repositories as well as client-specific databases. Key opinion leaders, pharmaceutical companies, healthcare providers, and medical aesthetic companies also aid in interpreting the factors that are likely to influence the growth of the hepatorenal syndrome treatment market in the coming years. Our research has been lauded and widely sought-after, thanks to the infinite supply of information that we obtain from company websites, industrial publications, and government statistics.

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Global Hepatorenal Syndrome Treatment Market: Market Snapshot

4. Market Overview

  • 4.1. Global Hepatorenal Syndrome Treatment Market: Type Overview
  • 4.2. Global Hepatorenal Syndrome Treatment Market: Key Industry Developments
  • 4.3. Market Dynamics
  • 4.4. Drivers and Restraints Snapshot Analysis
  • 4.5. Drivers
    • 4.5.1. Fast track and orphan drug designations
    • 4.5.2. Increase in strategic collaboration among key players
  • 4.6. Restraints
    • 4.6.1. Side-effects and risks related to drug usage
    • 4.6.2. Stringent regulatory requirements
  • 4.7. Opportunities
  • 4.8. Global Hepatorenal Syndrome Treatment Market Revenue Projections (US$ Mn), 2017-2027

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Regulatory Scenario by Region/Country
  • 5.3. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc)
  • 5.4. Prevalence of Liver & Kidney Diseases by Region/Globally

6. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

  • 6.1. Introduction
  • 6.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
    • 6.2.1. Type 1 Hepatorenal Syndrome
    • 6.2.2. Type 2 Hepatorenal Syndrome
  • 6.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Type
  • 6.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Type

7. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

  • 7.1. Introduction
  • 7.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
    • 7.2.1. Therapeutics
      • 7.2.1.1. Terlivaz
      • 7.2.1.2. Glypressin
      • 7.2.1.3. Lucassin
      • 7.2.1.4. Hepatoren
    • 7.2.2. Surgical Treatment
      • 7.2.2.1. Liver Transplantation
      • 7.2.2.2. Surgical Shunting
        • 7.2.2.2.1. Peritoneovenous Shunting
        • 7.2.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
        • 7.2.2.2.3. Others
      • 7.2.2.3. Renal Replacement Therapy
      • 7.2.2.4. Others
  • 7.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment
  • 7.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Treatment

8. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

  • 8.1. Introduction
  • 8.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Ambulatory Surgical Centers
    • 8.2.3. Academic & Research Institutes
    • 8.2.4. Others
  • 8.3. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user
  • 8.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by End-user

9. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

  • 9.1. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Region, 2017-2027
    • 9.1.1. North America
    • 9.1.2. Europe
    • 9.1.3. Asia Pacific
    • 9.1.4. Latin America
    • 9.1.5. Middle East & Africa
  • 9.2. Global Hepatorenal Syndrome Treatment Market Analysis, by Region
  • 9.3. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Region

10. North America Hepatorenal Syndrome Treatment Market Analysis

  • 10.1. North America Hepatorenal Syndrome Treatment Market
  • 10.2. North America Hepatorenal Syndrome Treatment Market Overview
  • 10.3. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
    • 10.3.1. Type 1 Hepatorenal Syndrome
    • 10.3.2. Type 2 Hepatorenal Syndrome
  • 10.4. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
    • 10.4.1. Therapeutics
      • 10.4.1.1. Terlivaz
      • 10.4.1.2. Glypressin
      • 10.4.1.3. Lucassin
      • 10.4.1.4. Hepatoren
    • 10.4.2. Surgical Treatment
      • 10.4.2.1. Liver Transplantation
      • 10.4.2.2. Surgical Shunting
        • 10.4.2.2.1. Peritoneovenous Shunting
        • 10.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
        • 10.4.2.2.3. Others
      • 10.4.2.3. Renal Replacement Therapy
    • 10.4.3. Others
  • 10.5. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
    • 10.5.1. Hospitals & Clinics
    • 10.5.2. Ambulatory Surgical Centers
    • 10.5.3. Academic & Research Institutes
    • 10.5.4. Others
  • 10.6. North America Hepatorenal Syndrome Treatment Market Forecast, by Country
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. North America Hepatorenal Syndrome Treatment Market Attractiveness Analysis
    • 10.7.1. By Type
    • 10.7.2. By Treatment
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Hepatorenal Syndrome Treatment Market Analysis

  • 11.1. Europe Hepatorenal Syndrome Treatment Market
  • 11.2. Europe Hepatorenal Syndrome Treatment Market Overview
  • 11.3. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
    • 11.3.1. Type 1 Hepatorenal Syndrome
    • 11.3.2. Type 2 Hepatorenal Syndrome
  • 11.4. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
    • 11.4.1. Therapeutics
      • 11.4.1.1. Terlivaz
      • 11.4.1.2. Glypressin
      • 11.4.1.3. Lucassin
      • 11.4.1.4. Hepatoren
    • 11.4.2. Surgical Treatment
      • 11.4.2.1. Liver Transplantation
      • 11.4.2.2. Surgical Shunting
        • 11.4.2.2.1. Peritoneovenous Shunting
        • 11.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
        • 11.4.2.2.3. Others
      • 11.4.2.3. Renal Replacement Therapy
    • 11.4.3. Others
  • 11.5. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
    • 11.5.1. Hospitals & Clinics
    • 11.5.2. Ambulatory Surgical Centers
    • 11.5.3. Academic & Research Institutes
    • 11.5.4. Others
  • 11.6. Europe Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region
    • 11.6.1. U.K.
    • 11.6.2. France
    • 11.6.3. Germany
    • 11.6.4. Spain
    • 11.6.5. Italy
    • 11.6.6. Rest of Europe
  • 11.7. Europe Hepatorenal Syndrome Treatment Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Treatment
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis

  • 12.1. Asia Pacific Hepatorenal Syndrome Treatment Market Key Findings
  • 12.2. Asia Pacific Hepatorenal Syndrome Treatment Market Overview
  • 12.3. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
    • 12.3.1. Type 1 Hepatorenal Syndrome
    • 12.3.2. Type 2 Hepatorenal Syndrome
  • 12.4. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
    • 12.4.1. Therapeutics
      • 12.4.1.1. Terlivaz
      • 12.4.1.2. Glypressin
      • 12.4.1.3. Lucassin
      • 12.4.1.4. Hepatoren
    • 12.4.2. Surgical Treatment
      • 12.4.2.1. Liver Transplantation
      • 12.4.2.2. Surgical Shunting
        • 12.4.2.2.1. Peritoneovenous Shunting
        • 12.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
        • 12.4.2.2.3. Others
      • 12.4.2.3. Renal Replacement Therapy
    • 12.4.3. Others
  • 12.5. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
    • 12.5.1. Hospitals & Clinics
    • 12.5.2. Ambulatory Surgical Centers
    • 12.5.3. Academic & Research Institutes
    • 12.5.4. Others
  • 12.6. Asia Pacific Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region
    • 12.6.1. China
    • 12.6.2. India
    • 12.6.3. Japan
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Treatment
    • 12.7.3. By End-user
    • 12.7.4. By Country/Sub-region

13. Latin America Hepatorenal Syndrome Treatment Market Analysis

  • 13.1. Latin America Hepatorenal Syndrome Treatment Market Key Findings
  • 13.2. Latin America Hepatorenal Syndrome Treatment Market Overview
  • 13.3. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
    • 13.3.1. Type 1 Hepatorenal Syndrome
    • 13.3.2. Type 2 Hepatorenal Syndrome
  • 13.4. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
    • 13.4.1. Therapeutics
      • 13.4.1.1. Terlivaz
      • 13.4.1.2. Glypressin
      • 13.4.1.3. Lucassin
      • 13.4.1.4. Hepatoren
    • 13.4.2. Surgical Treatment
      • 13.4.2.1. Liver Transplantation
      • 13.4.2.2. Surgical Shunting
        • 13.4.2.2.1. Peritoneovenous Shunting
        • 13.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
        • 13.4.2.2.3. Others
      • 13.4.2.3. Renal Replacement Therapy
    • 13.4.3. Others
  • 13.5. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
    • 13.5.1. Hospitals & Clinics
    • 13.5.2. Ambulatory Surgical Centers
    • 13.5.3. Academic & Research Institutes
    • 13.5.4. Others
  • 13.6. Latin America Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Latin America Hepatorenal Syndrome Treatment Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Treatment
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Hepatorenal Syndrome Treatment Market Analysis

  • 14.1. Middle East & Africa Hepatorenal Syndrome Treatment Market
  • 14.2. Middle East & Africa Hepatorenal Syndrome Treatment Market Overview
  • 14.3. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
    • 14.3.1. Type 1 Hepatorenal Syndrome
    • 14.3.2. Type 2 Hepatorenal Syndrome
  • 14.4. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
    • 14.4.1. Therapeutics
      • 14.4.1.1. Terlivaz
      • 14.4.1.2. Glypressin
      • 14.4.1.3. Lucassin
      • 14.4.1.4. Hepatoren
    • 14.4.2. Surgical Treatment
      • 14.4.2.1. Liver Transplantation
      • 14.4.2.2. Surgical Shunting
        • 14.4.2.2.1. Peritoneovenous Shunting
        • 14.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
        • 14.4.2.2.3. Others
      • 14.4.2.3. Renal Replacement Therapy
    • 14.4.3. Others
  • 14.5. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
    • 14.5.1. Hospitals & Clinics
    • 14.5.2. Ambulatory Surgical Centers
    • 14.5.3. Academic & Research Institutes
    • 14.5.4. Others
  • 14.6. Middle East & Africa Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Treatment
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competitive Landscape

  • 15.1. Company Profiles
    • 15.1.1. Cumberland Pharmaceuticals, Inc.
      • 15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.1.2. Financials
      • 15.1.1.3. Recent Developments
      • 15.1.1.4. Strategy
    • 15.1.2. Orphan Therapeutics, LLC.
      • 15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.2.2. Financials
      • 15.1.2.3. Recent Developments
      • 15.1.2.4. Strategy
    • 15.1.3. BioVie Inc.
      • 15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.3.2. Financials
      • 15.1.3.3. Recent Developments
      • 15.1.3.4. Strategy
    • 15.1.4. Mallinckrodt Pharmaceuticals
      • 15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.4.2. Financials
      • 15.1.4.3. Recent Developments
      • 15.1.4.4. Strategy

List of Tables

  • TABLE 1 Global Hepatorenal Syndrome Treatment Pipeline Analysis (1/5)
  • TABLE 2 Global Hepatorenal Syndrome Treatment Pipeline Analysis (2/5)
  • TABLE 3 Global Hepatorenal Syndrome Treatment Pipeline Analysis (3/5)
  • TABLE 4 Global Hepatorenal Syndrome Treatment Pipeline Analysis (4/5)
  • TABLE 5 Global Hepatorenal Syndrome Treatment Pipeline Analysis (5/5)
  • TABLE 6 Comparative Analysis of Orphan Drug Policies
  • TABLE 7 Worldwide Epidemiology of Liver Diseases
  • TABLE 8 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2027
  • TABLE 9 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 10 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2027
  • TABLE 11 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017-2027
  • TABLE 12 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017-2027
  • TABLE 13 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 14 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • TABLE 15 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • TABLE 16 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2027
  • TABLE 17 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 18 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2027
  • TABLE 19 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017-2027
  • TABLE 20 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017-2027
  • TABLE 21 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 22 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 23 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2027
  • TABLE 24 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 25 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2027
  • TABLE 26 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017-2027
  • TABLE 27 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017-2027
  • TABLE 28 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 29 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 30 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2027
  • TABLE 31 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 32 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2027
  • TABLE 33 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017-2027
  • TABLE 34 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017-2027
  • TABLE 35 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 36 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 37 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2027
  • TABLE 38 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 39 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2027
  • TABLE 40 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017-2027
  • TABLE 41 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017-2027
  • TABLE 42 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2027
  • TABLE 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 46 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2027
  • TABLE 47 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017-2027
  • TABLE 48 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017-2027
  • TABLE 49 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027

List of Figures

  • FIG. 1 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, 2017-2027
  • FIG. 2 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type (2018)
  • FIG. 3 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment (2018)
  • FIG. 4 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user (2018)
  • FIG. 5 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region (2018)
  • FIG. 6 Regulatory Approval Process - U.S.
  • FIG. 7 Regulatory Approval Process - Europe
  • FIG. 8 Regulatory Approval Process - Japan
  • FIG. 9 Regulatory Approval Process - China
  • FIG. 10 Revision of Drug Administration Law & Drug Registration Regulation
  • FIG. 11 Drug Approval Process in China - Step 1
  • FIG. 12 Drug Approval Process in China - Step 2
  • FIG. 13 Drug Approval Process in China - Step 3
  • FIG. 14 Recent CFDA Regulatory Reforms to Support Innovative Drugs
  • FIG. 15 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type, 2018 and 2027
  • FIG. 16 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Type, 2019-2027
  • FIG. 17 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 1 Hepatorenal Syndrome, 2017-2027
  • FIG. 18 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 2 Hepatorenal Syndrome, 2017-2027
  • FIG. 19 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment, 2018 and 2027
  • FIG. 20 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 21 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Therapeutics, 2017-2027
  • FIG. 22 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Treatment, 2017-2027
  • FIG. 23 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user, 2018 and 2027
  • FIG. 24 Global Hepatorenal Syndrome Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 25 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals & Clinics, 2017-2027
  • FIG. 26 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2017-2027
  • FIG. 27 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Academic & Research Institutes, 2017-2027
  • FIG. 28 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017-2027
  • FIG. 29 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region, 2018 and 2027
  • FIG. 30 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Region, 2019-2027
  • FIG. 31 North America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • FIG. 32 North America Hepatorenal Syndrome Treatment Market Value Share (%), by Country, 2018 and 2027
  • FIG. 33 North America Hepatorenal Syndrome Treatment Market Attractiveness, by Country, 2019-2027
  • FIG. 34 Europe Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • FIG. 35 Europe Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027
  • FIG. 36 Europe Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 37 Asia Pacific Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • FIG. 38 Asia Pacific Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027
  • FIG. 39 Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 40 Latin America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • FIG. 41 Latin America Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027
  • FIG. 42 Latin America Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • FIG. 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027
  • FIG. 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 46 Cumberland Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 47 Cumberland Pharmaceuticals, Inc., Breakdown of Net Sales, by Region, 2018
  • FIG. 48 Mallinckrodt Pharmaceuticals, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 49 Mallinckrodt Pharmaceuticals, R&D Expenses, 2015-2018
  • FIG. 50 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Region, 2018
  • FIG. 51 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Business Segment, 2018
Back to Top